Peer-reviewed publications:

1. Klein M, Wild K, McTiernan N, Arnesen T, Sinning I* (2026) NatA engages in multi-factor complexes at the ribosomal polypeptide tunnel exit. Nature Communications, 17(1):884.
    
2. Lundekvam M, Kjosås I, McTiernan N* (2025) Functional assessment of N-terminal acetyltransferase variants. Methods in Enzymology, 718:165-184.
    
3. Caiella A, McTiernan N, Aksnes H* (2025) N-terminal acetylation-specific antibodies: Specificity determination by mass spectrometry and utilization in in vitro acetylation assays. Methods in Enzymology, 718:129-165.
    
4. McTiernan N*, Kjosås I*, Arnesen T* (2025) Illuminating the impact of N-terminal acetylation: from protein to physiology. Nature Communications, 16(1):703.
    
5. Arnesen T*, Kjosås I, McTiernan N* (2024) Protein N-terminal acetylation is entering the degradation end game. Nature Reviews Molecular Cell Biology, 25(5):335-336.
    
6. Heathcote KC, Keeley TP, Myllykoski M, Lundekvam M, McTiernan N, Akter S, Masson N, Ratcliffe PJ*, Arnesen T*, Flashman E* (2024) N-terminal cysteine acetylation and oxidation patterns may define protein stability. Nature Communications, 15(1):5360.
    
7. Lundekvam M, Arnesen T*, McTiernan N* (2023) Using cell lysates to assess N-terminal acetyltransferase activity and impairment. Methods in Enzymology, 686:29-43.
    
8. Aksnes H*, McTiernan N, Arnesen T* (2023) NATs at a glance. Journal of Cell Science, 136(14):jcs260766.
    
9. McTiernan N, Tranebjærg L, Bjørheim AS, Hogue JS, Wilson WG, Schmidt B, Boerrigter MM, Nybo ML, Smeland MF, Tümer Z, Arnesen T* (2022) Biochemical analysis of novel NAA10 variants suggests distinct pathogenic mechanisms involving impaired protein N-terminal acetylation. Human Genetics, 141(8):1355-1369.
    
10. McTiernan N, Gill H, Prada CE, Pachajoa H, Lores J, CAUSES study, Arnesen T* (2021) NAA10 p.(N101K) disrupts N-terminal acetyltransferase complex NatA and is associated with developmental delay and hemihypertrophy. European Journal of Human Genetics, 29(2):280-288.
     
11. Ree R, Krogstad K, McTiernan N, Jakobsson ME, Arnesen T (2021) Hydroxylation of the Acetyltransferase NAA10 Trp38 Is Not an Enzyme-Switch in Human Cells. International Journal of Molecular Sciences, 22(21):11805.
     
12. Kweon HY, Lee MN*, Dorfel M, Seo S, Gottlieb L, PaPazyan T, McTiernan N, Ree R, Bolton D, Garcia A, Flory M, Crain J, Sebold A, Lyons S, Ismail A, Marchi E, Sonn SK, Jeong SJ, Jeon S, Ju S, Conway SJ, Kim T, Kim HS, Lee C, Roh TY, Arnesen T, Marmorstein R, Oh GT*, Lyon GJ* (2021) Naa12 compensates for Naa10 in mice in the amino-terminal acetylation pathway. eLife, 10:e65952.
     
13. Deng S, McTiernan N, Wei X, Arnesen T, Marmorstein R* (2020) Molecular basis for N-terminal acetylation by human NatE and its modulation by HYPK. Nature Communications, 11(1):818. 
     
14. McTiernan N, Darbakk C, Ree R, Arnesen T* (2020) NAA10 p.(D10G) and NAA10 p.(L11R) Variants Hamper Formation of the NatA N-Terminal Acetyltransferase Complex. International Journal of Molecular Sciences, 21(23):8973.
     
15. Bader I#, McTiernan N#, Darbakk C#, Boltshauser E, Ree R, Ebner S, Mayr JA, Arnesen T (2020) Severe syndromic ID and skewed X-inactivation in a girl with NAA10 dysfunction and a novel heterozygous de novo NAA10 p.(His16Pro) variant - a case report. BMC Medical Genetics, 21(1):153.
     
16. McTiernan N#, Støve SI#, Aukrust I, Mårli MT, Myklebust LM, Houge G*, Arnesen T* (2018) NAA10 dysfunction with normal NatA-complex activity in a girl with non-syndromic ID and a de novo NAA10 p.(V111G) variant - a case report. BMC Medical Genetics, 19(1):47.
     
17. Støve SI, Blenski M, Stray-Pedersen A, Wierenga KJ, Jhangiani SN, Akdemir ZC, Crawford D, McTiernan N, Myklebust LM, Purcarin G, McNall-Knapp R, Wadley A, Belmont JW, Kim JJ, Lupski JR, Arnesen T* (2018) A novel NAA10 variant with impaired acetyltransferase activity causes developmental delay, intellectual disability, and hypertrophic cardiomyopathy. European Journal of Human Genetics, 26(9):1294-1305.